EGFR and non-small cell lung carcinoma: Therefore, we aimed to evaluate the efficacy and safety of ICIs addition in patients with EGFR‐mutated NSCLC who progressed on EGFR‐TKI therapy, and to conduct a systematic review and network meta‐analysis (NMA) to provide reference for clinical practice and future research.